AAPB White Paper
Application of Biofeedback to Diabetes Mellitus
Angele McGrady, Ph.D.
There are two major types of diabetes.Type I, insulin dependent diabetes (IDDM),
accounts for approximately 20% of individuals with diabetes. In this type the
pancreas makes little or no insulin and individuals require daily exogenous
insulin injections to maintain control of blood glucose.In Type II, noninsulin
dependent diabetes (NIDDM), the pancreas is producing insulin at reduced, normal
or above normal levels but the tissues in the body have developed a resistance
to insulin. Glucose is prevented from entering the cells and blood glucose
levels increase. Oral medications are used to stimulate the pancreas and to
decrease insulin resistance.NIDDM accounts for 80% of individuals diagnosed with
diabetes.Heredity and obesity increase the chances of an individual developing
NIDDM.
Besides using the hypoglycemic agents (insulin and sulfonylurea)
individuals with diabetes must engage in health maintenance behaviors. Weight
control, adequate nutrition, physical exercise and regular monitoring of blood
glucose are critical components of self management.
Stressful life events and daily hassles cause blood glucose to increase,
consequently increasing the requirements for insulin. During stress, cortisol is
released from the adrenal cortex and sympathetic adrenal medullary activity
increases, promoting high blood glucose levels and interfering with the actions
of insulin. may omit their regular exercise, not pay attention to their diet, or
fail to take the hypoglycemic medications.
Biofeedback is a technique by which persons learn to be aware of and
control specific physiological processes. Biofeedback is usually coupled with
relaxation training to reduce the arousal mediated by the nervous and endocrine
systems. Since the effects of stress on blood glucose are clear, treatment
directed to the reduction of the arousal response or to improve coping abilities
can benefit individuals with diabetes. Thus, biofeedback has the potential to be
an effective adjunct to hypoglycemic agents in individuals with IDDM and NIDDM.
A 12 to 15-session treatment plan comprised of
diaphragmatic breathing, electromyograph and thermal biofeedback, autogenic and
progressive relaxation is recommended. The treatment should be implemented
gradually with knowledge of the individual's blood glucose values. Home practice
of relaxation is recommended at times of the day when patients are unlikely to
be experiencing hypoglycemia (low blood glucose). Multiple daily measurements of
blood glucose for 2-3 weeks are necessary to establish an accurate pretreatment
average. Regular monitoring of blood glucose should continue during treatment so
that the individual's progress and any changes in blood glucose can be tracked.
A clinical nurse specialist or diabetes educator is a valuable part of the
treatment team since this individual has expertise in assessing the effects of
diet, exercise, illness and other factors on blood glucose. Since blood glucose
levels may fluctuate dramatically with exercise or illness, particularly if the
individual's glucose values are usually erratic, surveillance of blood glucose
by patients and staff must be maintained. Blood glucose numbers are expressed in
mg/dl or mM/ 1 (milligrams per deciliter or millimoles per liter).
After treatment is completed, a two-week period of data
collection is used to compare the average pretreatment values to posttreatment
of daily blood glucose. Other valuable indices of progress are percent of blood
glucose values above 200 mg/dl, percent of fasting blood glucose values at
target (80-120 mg/dl) and dosage of the hypoglycemic agent. The patient's
physician should be contacted for any changes in dosage or for any serious
unresolved glycemic problems.
In summary, biofeedback and relaxation can be very
effective in assisting individuals with diabetes to maintain better control over
their blood glucose and to decrease the requirement for hypoglycemic agents.
This treatment, however, cannot be used as a substitute for hypoglycemic agents
and must be carried out in conjunction with regular self monitoring of blood
glucose.
Bailey, B.K., McGrady, A.V. and Good, M. (1990).
Management of a patient with insulin dependent diabetes mellitus learning
biofeedback-assisted relaxation. Diabetes Education, 16 (3), 201-204.
Bailey, B.K., Good, M., and McGrady, A. (1990). Clinical observations
on behavioral' treatment of a patient with insulin-dependent diabetes
mellitus. Published erratum appears in Biofeedback and Self-Regulation.
15 (1), 7-13.
Feinglos, M.N., Hastedt, P. and Surwit, R.S. Effects of relaxation
therapy on patients with Type I diabetes mellitus. Diabetes Care.
10:72-75, 1987.
Guthrie, D., Moeller, T. and Guthrie, R. Biofeedback
and its application to the stabilization and control of diabetes mellitus.
American Journal of Clinical Biofeedback. 6(2):82-87, 1983.
Landis, B., Jovanovic, L., Landis, E., Peterson, C.M.,
Groshen, S., Johnson, K. and Miller, N.E. Effects of stress reduction on
daily glucose range in previously stabilized insulindependent diabetic
patients. Diabetes Care. 8:624-626, 1985.
McGrady, A., Bailey, B.K. and Good, M.P. Controlled study of
biofeedback-assisted relaxation in Type I diabetes. Diabetes Care.
14(5):360-365, 1991.
© 1995
Association for Applied Psychophysiology and Biofeedback
|